Cost-effectiveness of combination therapy of polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisolone for previously untreated diffuse large B-cell lymphoma in Japan.
Takashi MizuokaHiroyuki SakamakiShigeo FujiShota SaitoTatsunori MurataShinya OhnoNaoki InubashiriTomoha OshimaKazuhito YamamotoPublished in: Journal of medical economics (2023)
This study suggests that Pola + R-CHP is a cost-effective treatment for previously untreated DLBCL in Japan under the public health insurance system.